<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462550</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2017/0117</org_study_id>
    <nct_id>NCT03462550</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Laryngeal Mask Airway Supreme With the Laryngeal Mask Airway Protector In the Ambulatory Surgery Unit</brief_title>
  <official_title>A Randomized Study Comparing the Laryngeal Mask Airway Supreme With the Laryngeal Mask Airway Protector In the Ambulatory Surgery Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Laryngeal Mask Airway is a supraglottic airway device that has been used in anesthesia&#xD;
      for decades. Now the third generation (LMA Supreme) is commonly used. Recently the LMA&#xD;
      Protector is manufactured.&#xD;
&#xD;
      The primary hypothesis of this study is: the oropharyngeal leak pressure of the LMA Protector&#xD;
      is 5 cmH2O higher than the oropharyngeal leak pressure of the LMA Supreme. Secondary outcome&#xD;
      measures are: ease of insertion, fibreoptic position, ease of gastric tube placement.&#xD;
&#xD;
      Differences between LMA Supreme and LMA Protector are: the LMA protector has a dual gastric&#xD;
      drainage channel, LMA supreme one. For LMA protector, airway tube and cuff are 100% silicone,&#xD;
      in LMA supreme the cuff is polivinylchloride. Silicone cuffs have shown to reduce risk of&#xD;
      sore throat and achieve higher seal pressures. There are no aperture bars in the LMA&#xD;
      protector (2 in LMA supreme). The tube of LMA protector is more flexible. An integrated cuff&#xD;
      pressure indicator for single use airway management devices that enables continuous cuff&#xD;
      pressure monitoring only in the LMA protector.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Outpatients planned for elective minor surgery, routinely done with LMA, will be asked&#xD;
           to participate in the study.&#xD;
&#xD;
        2. The patient is preoxygenated for 3 min. Anaesthesia is induced with 0.15 mcg/kg&#xD;
           sufentanil and 1 - 4 mg/kg propofol. Routine monitoring is used together with&#xD;
           BIS-monitoring. No neuromuscular relaxing agent is used. Patients lungs will be&#xD;
           ventilated with a face mask for 3 min and then the LMA will be inserted while the neck&#xD;
           of the patient is flexed, the head extended. LMA cuff is completely deflated. The LMA is&#xD;
           inserted using a single-handed rotational technique. Failed insertion is defined as:&#xD;
           failed passage in the pharynx, malposition (air leak) and ineffective ventilation&#xD;
           (expired tidal volume&lt;25% of administered volume). The time between picking up the LMA&#xD;
           and successful placement is recorded. When failed on the first attempt the LMA will be&#xD;
           inserted with a digital guided technique. A Third attempt will be a gum-elastic-bougie&#xD;
           guided technique.&#xD;
&#xD;
        3. Oropharyngeal leak pressure is determined at 0-40ml cuff volume in 10 ml increments. The&#xD;
           expiratory valve of the circle system is closed at a fixed gas flow of 3 l/min and&#xD;
           noting the airway pressure at equilibrium (max allowed 40 cmH2O)&#xD;
&#xD;
        4. Fiber optic position: 4=only vocal cords visible, 3=vocal cords + posterior epiglottis,&#xD;
           2=vocal cords + anterior epiglottis, 1=vocal cords not seen. Fiber optic position will&#xD;
           only be evaluated if available at the moment of the study.&#xD;
&#xD;
        5. Cuff pressure is set at 65 cmH2O using a manometer and patients lungs are ventilated at&#xD;
           a tidal volume of 10 ml/kg, at a respiratory rate of 12/min. Presence of air leak is&#xD;
           detected by listening over the mouth, gastric air leak (stethoscope over epigastrium,&#xD;
           larynx, drain tube air leaks (lubricant over proximal end) or end-tidal CO2 &gt; 45 mmHg.&#xD;
           Respiratory settings are changed at the discretion of the anesthesiologist after&#xD;
           successful placement.&#xD;
&#xD;
        6. Correct gastric tube placement is assessed by suction of fluid. Cardiorespiratory data&#xD;
           are collected: bradycardia &gt;100/min, tachycardia &gt;, hypotension, hypoxaemia&#xD;
&#xD;
        7. Upon removal of the LMA at the end of the procedure the device will be checked for blood&#xD;
           staining.&#xD;
&#xD;
        8. At discharge from day surgery unit patients will be asked for presence of sore throat.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Airway Leak Pressure</measure>
    <time_frame>perioperative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Airway Complication of Anesthesia</condition>
  <arm_group>
    <arm_group_label>LMA Supreme</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMA Protector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laryngeal mask</intervention_name>
    <description>LMA insertion</description>
    <arm_group_label>LMA Protector</arm_group_label>
    <arm_group_label>LMA Supreme</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are planned for elective minor surgery in the ambulatory surgery unit,&#xD;
             who are ASA I or II or III, aged 19-71 years, whose operation is routinely done with a&#xD;
             Laryngeal Mask Airway in the supine position.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are excluded if they are &lt;19 or &gt;71 years, have an anticipated difficult&#xD;
             airway, a body mass index &gt; 35kg.m-2 or are at risk of aspiration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Coppens</last_name>
    <phone>3293325807</phone>
    <email>marc.coppens@uzgent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

